Autogene cevumeran is under clinical development by Genentech USA and currently in Phase II for Pancreatic Ductal Adenocarcinoma. According to GlobalData, Phase II drugs for Pancreatic Ductal Adenocarcinoma does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Autogene cevumeran LoA Report. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Autogene cevumeran overview

Autogene cevumeran is under development for the treatment of pancreatic ductal adenocarcinoma, previously untreated advanced melanoma, locally advanced or metastatic solid tumors such as non-small cell lung cancer, colorectal cancer, head and neck cancer squamous cell carcinoma, transitional cell carcinoma (urothelial cell carcinoma) including urethral cancer, ureters cancer, triple-negative breast cancer, bladder cancer, renal pelvis, renal cell carcinoma, melanoma, oral cavity cancer, oropharyngeal, hypopharyngeal and laryngeal cancer. The drug candidate is administered by intravenous route. It is a personalized cancer vaccine. It is developed based on iNeST (patient specific cancer antigen immune therapy) platform technology.

It was also under development for Merkel cell carcinoma, anal cancer, cervical cancer, hepatocellular cancer, MSI-H and MSI-low tumors and squamous cell carcinoma of skin.

Genentech USA overview

Genentech USA (Genentech), a subsidiary of F. Hoffmann-La Roche Ltd, is a biotechnology company that discovers, develops, manufactures and commercializes medicines to address serious medical needs. It offers drugs in various therapeutic areas including oncology, immunology, ophthalmology, metabolism, neurology, and infectious disease, among others. The company’s pipeline products include Emicizumab (RG6013, ACE910), a bispecific monoclonal antibody used to replace the function of protein in the blood clotting process; and Entrectinib (RXDX-101, RG6268), a CNS-active tyrosine-kinase inhibitor intended for the treatment of non-small cell lung cancer; among others. The company has partnership with BioLineRx, Charles River Laboratories International, Amunix, among others. Genentech is headquartered in South San Francisco, California, the US.

For a complete picture of Autogene cevumeran’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.